Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/01/25
End: 10/31/33
Due: 10/31/34
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Darolutamide Alone or in Combination With Standard Therapy Before Surgery for the Treatment of Stage II-IIIA, Androgen Receptor Positive, Triple-Negative Breast Carcinoma | NCT07016399 | Vandana Abramson | user2@example.com | None | 2025-09-01 | 2033-10-31 | 2034-10-31 | - | - | 2025-07-14 |